Shares of Moderna (MRNA) climbed Monday after the 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration (FDA) approved the drugmaker's new C൩OVID-19 vaccin𓆉e. 

Moderna said its new vaccine, mNEXSPIKE, showed a higher relative efficacy in a 澳洲幸运5官方开奖结果体彩网:clinical trial than its first FDA-approved COVID-19 vaccine and was approved "for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC)."

The Cambridge, Mass.-based company said it "expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA, the Company's approved respiratory syncytial virus (RSV) vaccine."

Moderna's original COVID-19 vaccine, Spikevax, generated $3.1 billion in sales last year.

Moderna shares rose 2% soon after markets opened but have lost nearly 35% of their value in 2025.